P. Meliante

Deconstructing Exceptional Responses to Immune Checkpoint Inhibition in Recurrent or Metastatic Head and Neck Carcinoma: A Site-Specific Clinical–Biological Synthesis

Simple Summary Recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains an aggressive disease with historically poor survival rates. Although the introduction of immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway has revolutionized the treatment landscape, only a minority of p...